The blockbuster GLP-1 drugs that reshaped the treatment of diabetes and obesity may help prevent multiple substance use disorders — and reduce their tragic outcomes, a large new study found.
Two withdrawals of recently submitted initial public offering (IPO) filings by drug developers, plus a dearth of new filings this month, suggest that the outlook for biopharma IPOs remains cloudy, ...
Evolve Science treats COA availability as a non-negotiable standard. By providing batch-level documentation for every product ...
A review in the Canadian Journal of Physiology and Pharmacology examines emerging evidence linking glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the gut microbiome, and obesity treatment ...
Hormone therapy for menopause is safer than doctors had previously thought, new research says. It may also bring unexpected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results